Thursday, April 7, 2011

Medical News

Medical News


Cancer risk reduced in schizophrenia patients

Posted: 07 Apr 2011 05:00 PM PDT

Results from a Taiwanese study suggest that patients with schizophrenia are less likely to develop most types of cancer than individuals without the mental health disorder.

Children with ADHD at increased risk for bipolar disorder

Posted: 07 Apr 2011 05:00 PM PDT

Children with attention-deficit hyperactivity disorder are at increased risk for developing bipolar disorder, suggest results from an Italian study.

Five-yearly surveillance unnecessary in low-risk colorectal cancer patients

Posted: 07 Apr 2011 05:00 PM PDT

Low-risk patients with a history of less than three non-advanced colorectal adenomas have a similar 5-year colorectal cancer risk to individuals with no history of adenoma, Korean study results indicate.

Rivaroxaban effective, but causes more bleeding than enoxaparin

Posted: 06 Apr 2011 05:00 PM PDT

Rivaroxaban is noninferior in efficacy to enoxaparin for prevention of venous thromboembolism in acutely ill patients, but causes significantly higher rates of bleeding, show results from the MAGELLAN trial.

Stroke risk declines after cessation of HRT

Posted: 06 Apr 2011 05:00 PM PDT

The increased risk for stroke among women taking hormone replacement therapy dissipates soon after stopping treatment, shows follow-up of the Women's Health Initiative.

Poor physical health may indicate worse breast cancer outcome

Posted: 06 Apr 2011 05:00 PM PDT

Improving the physical health of breast cancer survivors may reduce their risk for recurrence and death, researchers reported at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

BMI in adolescence predicts CHD and diabetes risk later in life

Posted: 06 Apr 2011 05:00 PM PDT

An elevated body mass index in adolescence, but within the range currently considered normal, increases the risk for coronary heart disease and diabetes later in life, US researchers report.

Novel lipid parameters no better than conventional measures for CVD risk prediction

Posted: 06 Apr 2011 05:00 PM PDT

Results of a US study do not support the routine use of novel lipid parameters to assess future cardiovascular disease risk.

COPD not just a disease among smokers

Posted: 06 Apr 2011 05:00 PM PDT

Research indicates that doctors should not rule out a diagnosis of chronic obstructive pulmonary disease in people who have never smoked.

BMI in adolescence predicts CHD and diabetes risk later in life

Posted: 06 Apr 2011 05:00 PM PDT

An elevated body mass index in adolescence, but within the range currently considered normal, increases the risk for coronary heart disease and diabetes later in life, US researchers report.

Increased CV, death risk in diabetics largely due to coexistent hypertension

Posted: 06 Apr 2011 05:00 PM PDT

Results from a subanalysis of the Framingham Heart Study suggest that the increased risk for death and cardiovascular events known to occur in patients with diabetes is primarily due to concomitant hypertension.

Adverse outcome risk lower with metformin than other hypoglycemic agents

Posted: 06 Apr 2011 05:00 PM PDT

The risk for death and cardiovascular disease is lower among people with Type 2 diabetes treated with metformin monotherapy than with other commonly used insulin secretagogues, study results indicate.

Valsartan beats amlodipine for CHF risk, but not CV events, in hypertensive diabetics

Posted: 06 Apr 2011 05:00 PM PDT

The angiotensin II receptor blocker valsartan was comparable to the calcium channel blocker amlodipine at reducing blood pressure in Japanese patients with hypertension and diabetes or impaired glucose tolerance, according to results of the NAGOYA HEART study.

Candesartan, amlodipine offer similar benefits for paroxysmal AF with hypertension

Posted: 06 Apr 2011 05:00 PM PDT

Candesartan and amlodipine offer similar anti-arrhythmic benefits for paroxysmal atrial fibrillation associated with hypertension, an open-label trial suggests.

Valsartan beats amlodipine for CHF risk, but not CV events, in hypertensive diabetics

Posted: 06 Apr 2011 05:00 PM PDT

The angiotensin II receptor blocker valsartan was comparable to the calcium channel blocker amlodipine at reducing blood pressure in Japanese patients with hypertension and diabetes or impaired glucose tolerance, according to results of the NAGOYA HEART study.

OSCAR: Combination antihypertensives in elderly most effective in those with CVD

Posted: 06 Apr 2011 05:00 PM PDT

Elderly hypertensive patients with pre-existing cardiovascular disease derive the most benefit from treatment with a combination of an angiotensin II receptor blocker and a calcium channel blocker, show results from the OSCAR study.

RIVAL: Radial access PCI linked to reduced access-site complications

Posted: 06 Apr 2011 05:00 PM PDT

Both femoral and radial approaches to percutaneous coronary intervention are effective, but use of radial access is associated with a significantly lower rate of vascular access site complications than conventional femoral access, according to results of the RIVAL trial.

REMEDIAL II: Hydration system protects kidneys from contrast-induced injury

Posted: 06 Apr 2011 05:00 PM PDT

A system for aggressively hydrating patients undergoing imaging with contrast media is more effective at preventing acute contrast-induced kidney injury than standard prophylaxis with sodium bicarbonate and N-acetylcysteine, according to results of the REMEDIAL II trial.

Poor physical health may indicate worse breast cancer outcome

Posted: 06 Apr 2011 05:00 PM PDT

Improving the physical health of breast cancer survivors may reduce their risk for recurrence and death, researchers reported at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

Cardiac glycoside could reduce prostate cancer risk

Posted: 05 Apr 2011 05:00 PM PDT

The cardiac glycoside digoxin could be used as prostate cancer-prevention therapy, says a transdisciplinary team of researchers that evaluated the association between existing, tested, nonchemotherapy drugs and their effects on prostate cancer.

No comments:

Post a Comment